Period,symbol,NAV,sharesOutstanding,researchDevelopment,effectOfAccountingCharges,incomeBeforeTax,minorityInterest,netIncome,sellingGeneralAdministrative,grossProfit,ebit,operatingIncome,otherOperatingExpenses,interestExpense,extraordinaryItems,nonRecurring,otherItems,incomeTaxExpense,totalRevenue,totalOperatingExpenses,costOfRevenue,totalOtherIncomeExpenseNet,discontinuedOperations,netIncomeFromContinuingOps,netIncomeApplicableToCommonShares,capitalSurplus,totalLiab,totalStockholderEquity,otherCurrentLiab,totalAssets,commonStock,otherCurrentAssets,retainedEarnings,otherLiab,otherAssets,cash,totalCurrentLiabilities,propertyPlantEquipment,totalCurrentAssets,accountsPayable,changeToLiabilities,changeToOperatingActivities,changeInCash,totalCashFromOperatingActivities,depreciation,changeToNetincome,totalCashflowsFromInvestingActivities,capitalExpenditures,WC,language,region,quoteType,triggerable,quoteSourceName,regularMarketPrice,regularMarketTime,regularMarketChange,regularMarketOpen,regularMarketDayHigh,regularMarketDayLow,regularMarketVolume,currency,exchange,marketCap,gmtOffSetMilliseconds,esgPopulated,tradeable,marketState,priceHint,regularMarketChangePercent,regularMarketDayRange,market,exchangeDataDelayedBy,shortName,regularMarketPreviousClose,bid,ask,bidSize,askSize,messageBoardId,fullExchangeName,longName,financialCurrency,averageDailyVolume3Month,averageDailyVolume10Day,fiftyTwoWeekLowChange,fiftyTwoWeekLowChangePercent,fiftyTwoWeekRange,fiftyTwoWeekHighChange,fiftyTwoWeekHighChangePercent,fiftyTwoWeekLow,fiftyTwoWeekHigh,epsTrailingTwelveMonths,bookValue,fiftyDayAverage,fiftyDayAverageChange,fiftyDayAverageChangePercent,twoHundredDayAverage,twoHundredDayAverageChange,twoHundredDayAverageChangePercent,priceToBook,sourceInterval,exchangeTimezoneName,exchangeTimezoneShortName,Beta (5Y Monthly),52-Week Change 3,S&P500 52-Week Change 3,52 Week High 3,52 Week Low 3,50-Day Moving Average 3,200-Day Moving Average 3,Avg Vol (3 month) 3,Avg Vol (10 day) 3,Shares Outstanding 5,Implied Shares Outstanding 6,Float,% Held by Insiders 1,% Held by Institutions 1,"Shares Short (Jul 14, 2016) 4","Short Ratio (Jul 14, 2016) 4","Short % of Float (Jul 14, 2016) 4","Short % of Shares Outstanding (Jul 14, 2016) 4","Shares Short (prior month Jun 14, 2016) 4",Forward Annual Dividend Rate 4,Forward Annual Dividend Yield 4,Trailing Annual Dividend Rate 3,Trailing Annual Dividend Yield 3,5 Year Average Dividend Yield 4,Payout Ratio 4,Dividend Date 3,Ex-Dividend Date 4,Last Split Factor 2,Last Split Date 3,Fiscal Year Ends,Most Recent Quarter (mrq),Profit Margin,Operating Margin (ttm),Return on Assets (ttm),Return on Equity (ttm),Revenue (ttm),Revenue Per Share (ttm),Quarterly Revenue Growth (yoy),Gross Profit (ttm),EBITDA,Net Income Avi to Common (ttm),Diluted EPS (ttm),Quarterly Earnings Growth (yoy),Total Cash (mrq),Total Cash Per Share (mrq),Total Debt (mrq),Total Debt/Equity (mrq),Current Ratio (mrq),Book Value Per Share (mrq),Operating Cash Flow (ttm),Levered Free Cash Flow (ttm),index,zip,sector,fullTimeEmployees,longBusinessSummary,city,phone,state,compensationAsOfEpochDate,country,website,maxAge,address1,fax,industry
t0,GBIM,2150164,5751570,337897,,-862208,,-862208,933251,428025,-862208,-862208,,,,,,0,942750,1804958,514725,0,,-862208,-862208,228478265,7620793,2150164,3450582,9770957,5752,755958,-226333853,3475800,130645,8693718,4144993,190636,9449676,407672,-647538.0,259685.0,-1207004.0,-1207004.0,19085.0,23972.0,,,5304683,en-US,US,EQUITY,False,Delayed Quote,0.339,1630524665,-0.018000007,0.25,0.34,0.25,2600,USD,PNK,1949782,-14400000,False,False,POST,4,-5.042019,0.25 - 0.34,us_market,0,GLOBEIMMUNE INC,0.357,0.0,1.95,0,10,finmb_1497235,Other OTC,"GlobeImmune, Inc.",USD,17143,15066,0.23999998,2.4242423,0.099 - 5.46,-5.1210003,-0.9379121,0.099,5.46,-0.36,0.374,0.49166667,-0.15266669,-0.31050852,1.384471,-1.0454711,-0.75514114,0.9064171,15,America/New_York,EDT,1.86,,,5.46,0.099,0.4917,1.3845,17.14k,15.07k,5.75M,,4.37M,0.00%,0.02%,129.39k,0.1,3.49%,2.25%,114.55k,,,,,,0.00%,,,,,"Dec 30, 2015","Mar 30, 2016",-33.30%,-33.30%,-10.25%,-66.24%,6.21M,1.08,-20.60%,3.81M,-1.94M,-2.07M,-0.3600,,8.69M,1.51,,,2.28,0.37,-5.9M,-1.65M,Value,80027,Healthcare,2,"GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.",Louisville,303-625-2700,CO,1451520000,United States,http://www.globeimmune.com,86400,1450 Infinite Drive,303-625-2710,Biotechnology
t-1,GBIM,2988400,5751570,441258,,-795032,,-795032,1249242,815021,-895032,-895032,,,,,,0,1047914,1942946,232893,100000,,-795032,-795032,228454293,8517741,2988400,3450582,11506141,5752,1190053,-225471645,4292302,205645,9900722,4225439,209721,11090775,234070,-872663.0,222981.0,-1394825.0,-1408496.0,19553.0,16665.0,13671.0,,6865336,en-US,US,EQUITY,False,Delayed Quote,0.339,1630524665,-0.018000007,0.25,0.34,0.25,2600,USD,PNK,1949782,-14400000,False,False,POST,4,-5.042019,0.25 - 0.34,us_market,0,GLOBEIMMUNE INC,0.357,0.0,1.95,0,10,finmb_1497235,Other OTC,"GlobeImmune, Inc.",USD,17143,15066,0.23999998,2.4242423,0.099 - 5.46,-5.1210003,-0.9379121,0.099,5.46,-0.36,0.374,0.49166667,-0.15266669,-0.31050852,1.384471,-1.0454711,-0.75514114,0.9064171,15,America/New_York,EDT,1.86,,,5.46,0.099,0.4917,1.3845,17.14k,15.07k,5.75M,,4.37M,0.00%,0.02%,129.39k,0.1,3.49%,2.25%,114.55k,,,,,,0.00%,,,,,"Dec 30, 2015","Mar 30, 2016",-33.30%,-33.30%,-10.25%,-66.24%,6.21M,1.08,-20.60%,3.81M,-1.94M,-2.07M,-0.3600,,8.69M,1.51,,,2.28,0.37,-5.9M,-1.65M,Value,80027,Healthcare,2,"GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.",Louisville,303-625-2700,CO,1451520000,United States,http://www.globeimmune.com,86400,1450 Infinite Drive,303-625-2710,Biotechnology
t-2,GBIM,3754093,5751570,420586,,893602,,893602,930404,2365125,993602,993602,,,,,,0,2944947,1951345,579822,-100000,,893602,893602,228424954,9458166,3754093,3450582,13212259,5752,1586441,-224676613,5108804,100000,11295547,4349362,230271,12881988,285593,-1167600.0,-933288.0,-1069740.0,-1308177.0,20533.0,-121424.0,238437.0,-1594.0,8532626,en-US,US,EQUITY,False,Delayed Quote,0.339,1630524665,-0.018000007,0.25,0.34,0.25,2600,USD,PNK,1949782,-14400000,False,False,POST,4,-5.042019,0.25 - 0.34,us_market,0,GLOBEIMMUNE INC,0.357,0.0,1.95,0,10,finmb_1497235,Other OTC,"GlobeImmune, Inc.",USD,17143,15066,0.23999998,2.4242423,0.099 - 5.46,-5.1210003,-0.9379121,0.099,5.46,-0.36,0.374,0.49166667,-0.15266669,-0.31050852,1.384471,-1.0454711,-0.75514114,0.9064171,15,America/New_York,EDT,1.86,,,5.46,0.099,0.4917,1.3845,17.14k,15.07k,5.75M,,4.37M,0.00%,0.02%,129.39k,0.1,3.49%,2.25%,114.55k,,,,,,0.00%,,,,,"Dec 30, 2015","Mar 30, 2016",-33.30%,-33.30%,-10.25%,-66.24%,6.21M,1.08,-20.60%,3.81M,-1.94M,-2.07M,-0.3600,,8.69M,1.51,,,2.28,0.37,-5.9M,-1.65M,Value,80027,Healthcare,2,"GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.",Louisville,303-625-2700,CO,1451520000,United States,http://www.globeimmune.com,86400,1450 Infinite Drive,303-625-2710,Biotechnology
t-3,GBIM,2835341,5751570,580173,,-1304947,,-1304947,1181072,524517,-1304947,-1304947,,,,,,0,1277047,2581994,752530,0,,-1304947,-1304947,228399804,10699787,2835341,3340571,13535128,5752,727174,-225570215,5963441,100000,12365287,4736346,342667,13092461,703929,-643765.0,-145202.0,-1991428.0,-1981217.0,68219.0,44478.0,-10211.0,-10211.0,8356115,en-US,US,EQUITY,False,Delayed Quote,0.339,1630524665,-0.018000007,0.25,0.34,0.25,2600,USD,PNK,1949782,-14400000,False,False,POST,4,-5.042019,0.25 - 0.34,us_market,0,GLOBEIMMUNE INC,0.357,0.0,1.95,0,10,finmb_1497235,Other OTC,"GlobeImmune, Inc.",USD,17143,15066,0.23999998,2.4242423,0.099 - 5.46,-5.1210003,-0.9379121,0.099,5.46,-0.36,0.374,0.49166667,-0.15266669,-0.31050852,1.384471,-1.0454711,-0.75514114,0.9064171,15,America/New_York,EDT,1.86,,,5.46,0.099,0.4917,1.3845,17.14k,15.07k,5.75M,,4.37M,0.00%,0.02%,129.39k,0.1,3.49%,2.25%,114.55k,,,,,,0.00%,,,,,"Dec 30, 2015","Mar 30, 2016",-33.30%,-33.30%,-10.25%,-66.24%,6.21M,1.08,-20.60%,3.81M,-1.94M,-2.07M,-0.3600,,8.69M,1.51,,,2.28,0.37,-5.9M,-1.65M,Value,80027,Healthcare,2,"GlobeImmune, Inc., a biopharmaceutical company, focuses on developing therapeutic products for cancer and infectious diseases based on proprietary Tarmogen platform. Its product candidate includes GS-4774, which is in Phase 2 trials for the treatment of patients with chronically infected with hepatitis B virus, as well as with oral antiviral suppressive therapy. The company is also involved in developing GI-6301 for the treatment of cancers expressing the brachyury protein; and GI-6207 that is in Phase 2 clinical trials to treat medullary thyroid cancer. In addition, it is involved in developing GI-4000, which is in Phase 2b clinical trials for the treatment of resected pancreas cancer; and is in Phase 2 clinical trial to treat non-small cell lung cancer, as well as is in Phase 2 clinical trial for the treatment of colorectal cancer. Further, the company is involved in developing various other product candidates targeting various infectious diseases that are in preclinical development stage, which include GI-19000 to treat tuberculosis; GI-2010 for the treatment of human immunodeficiency virus; and GI-18000 for hepatitis D virus infection. It has strategic collaborations with Gilead Sciences, Inc. and Celgene Corporation. The company was formerly known as Ceres Pharmaceuticals, Inc. and changed its name to GlobeImmune, Inc. in May 2001. GlobeImmune, Inc. was founded in 1995 and is headquartered in Louisville, Colorado.",Louisville,303-625-2700,CO,1451520000,United States,http://www.globeimmune.com,86400,1450 Infinite Drive,303-625-2710,Biotechnology
